Life Science REIT

LABS

The current Life Science REIT (LABS) market capitalization is approximately £137.90M, based on its latest share price and shares outstanding. Market capitalization represents the total market value of a company's equity and is calculated by multiplying the current stock price by the number of shares outstanding. As a result, Life Science REIT's market cap fluctuates with changes in its share price and share count. Last updated: December 31, 2025 at 11:48 PM Eastern Time

In the most recently reported quarter, Life Science REIT (LABS) generated £5.38M in revenue, representing a +7.27% year over year change. Quarterly revenue results and expectations reflect underlying demand trends, pricing dynamics, product or service mix, seasonality, and broader macroeconomic conditions. Actual results may differ from consensus estimates as new information becomes available. Last updated: January 1, 2026 at 2:43 AM Eastern Time

In the most recently reported fiscal year, Life Science REIT (LABS) generated net income of £-13.98M, compared with £-21.71M in the prior fiscal year, representing a +35.61% year over year change. Net income may be positive or negative and can fluctuate materially from year to year due to changes in operating performance, non-recurring or one-time items, accounting treatments, capital structure, and broader macroeconomic conditions. Last updated: January 1, 2026 at 2:43 AM Eastern Time

As of the most recent reporting period, the company's debt-to-equity ratio stands at 0.54x, calculated as total debt divided by total shareholders' equity. A lower debt-to-equity ratio generally indicates a more conservative capital structure with less reliance on external borrowing, while a higher ratio suggests greater financial leverage and potentially higher sensitivity to interest rates, refinancing conditions, and earnings volatility. The debt-to-equity ratio should be interpreted in the context of the company's industry, business model, cash flow stability, and balance sheet composition. Last updated: January 1, 2026 at 2:43 AM Eastern Time

Based on the latest available data, Life Science REIT (LABS) is currently trading at a last twelve months (LTM) P/E ratio of -4.47x. The P/E ratio reflects how much investors are willing to pay today for a dollar of earnings and can vary meaningfully over time due to changes in profitability, growth expectations, margin outlook, and earnings volatility. Last updated: January 1, 2026 at 2:43 AM Eastern Time

In the most recently reported quarter, Life Science REIT (LABS) revenue was £5.38M. Earnings per share (EPS) for the quarter were £-0.04. Revenue and EPS surprises may be positive or negative and can influence near-term stock performance depending on expectations, forward guidance, and broader market and sector conditions. For a detailed history of analyst expectations versus reported results, view the full estimates vs. actuals track record here: 👉 Estimates vs. Actuals Last updated: January 1, 2026 at 2:43 AM Eastern Time

Analyst assessments of whether Life Science REIT (LABS) consensus price target is overvalued or undervalued are generally expressed relative to consensus valuation frameworks and price targets, rather than as an absolute judgment.Current share price: £0.39Consensus price target: £0.37Implied return: -6.09% An implied return above current levels indicates that, on average, analysts view the stock as trading below their estimated fair value. Conversely, an implied return below current levels suggests the stock may be fully valued or priced above consensus expectations. This content is for informational purposes only and does not constitute investment advice. Last updated: January 1, 2026 at 2:43 AM Eastern Time

Based on the latest available analyst coverage, Life Science REIT (LABS) currently carries a Hold consensus rating. Analysts' average LABS price target is £0.37. Relative to the current share price of £0.39, this suggests a potential price change of approximately -6.09%. Analyst views are forward-looking estimates and should not be considered investment advice. Last updated: January 1, 2026 at 2:43 AM Eastern Time

Like other publicly traded stocks, Life Science REIT (LABS) shares are bought and sold on stock exchanges such as LSE and other supported markets, depending on the listing. The most common way to buy shares is through an online brokerage account. To get started, you typically need to: Open an account with a licensed stock brokerComplete the broker's verification processFund your accountPlace a buy order for Life Science REIT (LABS) shares Trading involves risk, and investors should consider their financial objectives and risk tolerance before investing.

At the top right of this page, you'll see a star icon labeled Add to watchlist. Click it to add LABS to your watchlist.

Life Science REIT trades under the ticker symbol LABS on the LSE stock exchange. The ticker LABS is used to identify the company's common stock across trading platforms, market data providers, and regulatory filings.

Life Science REIT (LABS) operates in a highly competitive market with companies that often have different business models, geographic exposure, and end markets. While no two companies are identical, the following firms are generally considered the closest Life Science REIT (LABS) stock peers based on overlapping products, services, and competitive dynamics:Great Portland Estates (GPE)Workspace Group (WKP)Big Yellow Group (BYG)Unite Group (UTG)LondonMetric Property (LMP)British Land Company (BLND)SEGRO (SGRO) These peers may differ in size, business mix, financial profile, and strategic focus, but they are commonly referenced due to overlapping markets, customer segments, or competitive positioning relative to Life Science REIT.